IRADIMED posts Q3 2025 results press release

IRADIMED CORPORATION filed a Form 8-K to report that it issued a press release on November 3, 2025 announcing its financial results for the quarter ended September 30, 2025.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

IRADIMED CORPORATION filed a Form 8-K to report that it issued a press release on November 3, 2025 announcing its financial results for the quarter ended September 30, 2025.

The press release is furnished as Exhibit 99.1 and is designated as “furnished,” not “filed,” meaning it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did IRADIMED CORPORATION (IRMD) disclose in its November 3, 2025 Form 8-K?

IRADIMED CORPORATION disclosed that it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is furnished rather than filed under the Exchange Act.

Which period’s results are covered by IRMD’s November 3, 2025 press release?

The press release announced IRMD’s financial results for the quarter ended September 30, 2025. These quarterly results are referenced in Item 2.02 of the Form 8-K and provided in full within Exhibit 99.1 attached to the report.

How is Exhibit 99.1 treated in IRMD’s November 3, 2025 Form 8-K?

Exhibit 99.1, IRMD’s November 3, 2025 press release, is treated as furnished, not filed, under Section 18 of the Exchange Act. It is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

Who signed IRMD’s November 3, 2025 Form 8-K and in what capacity?

The Form 8-K was signed on behalf of IRADIMED CORPORATION by John Glenn. He signed the report in his capacity as Chief Financial Officer, acting as the duly authorized representative of the registrant under the Exchange Act.

What exhibits are included with IRMD’s November 3, 2025 Form 8-K?

The filing includes Exhibit 99.1, a press release dated November 3, 2025, and Exhibit 104, the cover page interactive data file in Inline XBRL format. These exhibits provide the detailed release and related structured data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/03/2025 - 08:30 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

Date of report (Date of earliest event reported): November 3, 2025

IRADIMED CORPORATION

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)


001-36534		73-1408526
(Commission File Number)		(IRS Employer Identification No.)


12705 Ingenuity Drive, Orlando, Florida		32826
(Address of principal executive offices)		(Zip Code)

(407) 677-8022

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:


Title of each class:	Trading Symbol	Name of each exchange on which registered:
Common stock, par value $0.0001	IRMD	NASDAQ Global Market

Item 2.02Results of Operations and Financial Condition.

On November 3, 2025, IRADIMED CORPORATION issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section. Furthermore, such information, including Exhibit 99.1, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.	Description

99.1	Press release dated November 3, 2025.

104	Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	IRADIMED CORPORATION

Date: November 3, 2025

	By:	/s/John Glenn
	Name:	John Glenn
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR